Drug Discovery@nature.com 29 June 2012

TABLE OF CONTENTS 29 June 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Structural & Molecular Biology FOCUS ON TRANSLATIONAL CONTROL Translational control has become a major focus of attention and research activity. The identification of a myriad of new factors and genome-wide targets as well as recent insights into eukaryotic ribosomes, translation initiation and control mechanisms will be discussed in four Reviews and one Perspective by leaders in the field. Access the Focus online: www.nature.com/nsmb/focus/translation   News Top Anticancer TLR agonists on the ropes doi:10.1038/nrd3775 Toll-like receptor agonists have hit another setback with the Phase II failure of Idera's IMO-2055. But they may still make a comeback if appropriate combinations with other drugs can be identified. Full Text Drug repurposing programmes get lift off doi:10.1038/nrd3776 What will schemes designed to get industry's discarded drug candidates into the hands of academic researchers deliver? Full Text Regulatory watch: Crossing the regulatory finish line doi:10.1038/nrd3774 Analysis indicates that the FDA reviews applications more rapidly than the EMA and Health Canada. Full Text Market watch: Upcoming market catalysts in Q3 2012 doi:10.1038/nrd3773 A positive trial result in Q3 2012 could drastically alter the outlook for three drugs that are designed around unproven molecular targets and that have faced substantial challenges. Full Text Analysis Top Bringing patient data into the open doi:10.1038/scibx.2012.644 Sage Bionetworks and the U.S. National Academy of Sciences conclude that breakthroughs in translational medicine require collecting large-scale patient data, including outcomes, and making it available to researchers. Full Text FDA advisory committee meeting outcomes doi:10.1038/nrd3747 This analysis of the outcomes of advisory committee meetings held by the US FDA over the past decade investigates issues such as the consistency between advisory committee votes and FDA approval decisions. Full Text Pipeline pioneers: Vismodegib doi:10.1038/nrd3753 First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma. Full Text Research Highlights Top Cancer: Of targets and anti-targets doi:10.1038/nrd3781 Polypharmacology is difficult to predict. Now, researchers have taken a systems pharmacology approach, identifying targets and anti-targets for the rational design of drugs with an optimized polypharmacological profile. Full Text Metabolic disorders: Heart microRNA provides new route to metabolic control doi:10.1038/nrd3779 Researchers have discovered a novel role of the heart in systemic metabolic control and suggest that miR-208a inhibition may have applications in the treatment of metabolic disorders. Full Text Anticancer drugs: Antipsychotic to anticancer agent? doi:10.1038/nrd3783 A new study has screened for compounds that selectively differentiate cancer stem cell-like cells and has identified dopamine receptor antagonists as promising candidates. Full Text Research & Reviews Top Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars doi:10.1038/nrd3746 This review looks at the analytical technologies available to assess biosimilars, focusing on the assessment of post-translational modifications, three-dimensional structures and protein aggregation. Full Text Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma doi:10.1038/nrd3745 This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities. Full Text IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells doi:10.1038/nm.2817 The identification of an IL-23-responsive CD4-CD8- T cell population points to new therapeutic targets for this group of rheumatic disorders. Full Text A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis doi:10.1038/nm.2826 Researchers have discovered a new axis that mediates the pathogenic progression of endometriosis, and suggest that the antibody to TNF-α etanercept might offer a therapy. Full Text Drug Discovery JOBS of the week Postdoctoral Researcher Marine Natural Products in Drug Discovery NUI Galway Ireland Post-Doctoral (WWang) - Target Identification and Drug Discovery - Immunobiology and Cancer Research Program Oklahoma Medical Research Foundation (OMRF) Tenure Track Assistant Professor Drug Design / Protein Crystallography (1,0 fte) University of Groningen, The Netherlands Research Associate, Drug Metabolism Pharmacokinetics Otsuka Postdoctoral Scholar � Enzymology and Drug Development Penn State College of Medicine More Science jobs from Drug Discovery EVENT Active Pharmaceutical Ingredient (API) and Drug Product Specifications 06.-08.08.12 US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.